Onco Wiki / drapeau rouge

Carcinome endométrial de stade I avec mutation pathogène POLE ou POLD1 exonucléase-domaine (...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-POLE-POLD1-ENDOMETRIAL-LOW-RISK
TypeSignal d’alerte
Étatreviewed 2026-04-29 | pending_clinical_signoff
MaladiesDIS-ENDOMETRIAL
SourcesSRC-ESGO-ENDOMETRIAL-2025 SRC-ESMO-ENDOMETRIAL-2022 SRC-NCCN-UTERINE-2025

Origine du drapeau rouge

DéfinitionStage I endometrial carcinoma with pathogenic POLE or POLD1 exonuclease-domain mutation (POLE-EDM / POLD1-EDM hypermutator phenotype) — TCGA / TransPORTEC integrated classification predicts excellent recurrence-free survival; adjuvant chemotherapy/radiotherapy is NOT indicated. NCCN Uterine 2025 endorses observation only.
Direction cliniquedésescalade
Catégoriescore de risque

Logique de déclenchement

{
  "all_of": [
    {
      "finding": "stage",
      "value": "I"
    },
    {
      "any_of": [
        {
          "finding": "BIO-POLE-HYPERMUTATOR",
          "value": "positive"
        },
        {
          "finding": "BIO-POLD1-HYPERMUTATOR",
          "value": "positive"
        }
      ]
    }
  ],
  "type": "biomarker_composite"
}

Notes

PORTEC-3 / TransPORTEC pooled analyses showed Stage I POLE-mutated endometrial carcinoma has near-100% recurrence-free survival without adjuvant therapy, even with high-grade morphology. POLD1-EDM is rarer but mechanistically equivalent and grouped with POLE in TCGA / ESGO-ESTRO integrated risk classification. de-escalate direction reflects avoidance of chemo/RT that would otherwise be considered for high-grade Stage I endometrial cancer. Routes care to IND-ENDOMETRIAL-STAGE-I-POLE-OBSERVATION. shifts_algorithm: empty because there is no Stage I endometrial algorithm yet — orchestrator should wire when ALGO-ENDOMETRIAL-STAGE-I lands. NCCN Uterine 2025 §UN-A and ESGO-ESTRO 2025 endometrial guideline both endorse observation for POLE-EDM Stage I.

Utilisé par

Biomarqueur